GlaxoSmithKline Buys PLIVA, Inc.'s R&D Drug Unit In $50 Million Deal

LONDON/ZAGREB Feb 14 (Reuters) - Europe’s biggest drugmaker, GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research), said on Tuesday it had bought the research institute of Croatian drug maker Pliva (PLV.ZA: Quote, Profile, Research) in a deal worth up to $50 million.

MORE ON THIS TOPIC